<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503178</url>
  </required_header>
  <id_info>
    <org_study_id>2006/098</org_study_id>
    <nct_id>NCT00503178</nct_id>
  </id_info>
  <brief_title>Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)</brief_title>
  <official_title>Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Highly selective irradiation requires accurate target definition by high-resolution
      three-dimensional imaging. Co-registration of FDG-PET and high-resolution CT might be the
      imaging modality of choice. This choice might target radiation therapy precisely to the
      intra-osseous volume that is responsible for pain and to spare selectively healthy bone in
      the vicinity of the metastasis. This strategy could result in equal anti-pain efficacy as
      conventional large volume radiotherapy, but could allow bone remodeling and preservation of
      bone structural strength in the vicinity and could lead to reduced toxicity to neighboring
      organs.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2006</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain assessment</measure>
    <time_frame>t0</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute toxicity</measure>
    <time_frame>t0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone remodeling</measure>
    <time_frame>t0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resulting volumes of the targets and functional active areas</measure>
    <time_frame>t0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mismatch and/or overlap areas</measure>
    <time_frame>t0</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Bone Metastases</condition>
  <arm_group>
    <arm_group_label>Patients undergoing imaging guided radiotherapy.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biological imaging guided antalgic radiotherapy</intervention_name>
    <description>Biological imaging guided antalgic radiotherapy is followed.</description>
    <arm_group_label>Patients undergoing imaging guided radiotherapy.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Painful bone metastasis of solid tumors

          -  A maximum number of bone metastases less or equal to 3

          -  Life expectancy &gt; 6 months

          -  Minimum age 21 years

          -  Signed informed consent

        Exclusion Criteria:

          -  Previous radiotherapy to the painful site

          -  Bone metastasis from malignant melanoma or renal cell carcinoma

          -  Associated fracture or extra-osseous component
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfried De Neve, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wilfried De Neve, MD, PhD</last_name>
    <phone>+ 32 9 332.30.22</phone>
    <email>wilfried.deneve@ugent.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wilfried De Neve, MD, PhD</last_name>
      <phone>+ 32 9 332.30.22</phone>
      <email>wilfried.deneve@ugent.be</email>
    </contact>
    <investigator>
      <last_name>Wilfried De Neve, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Website of the University Hospital Ghent</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2007</study_first_submitted>
  <study_first_submitted_qc>July 17, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2007</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

